• Skip to primary navigation
  • Skip to main content
Hillhouse

Hillhouse

Hillhouse builds businesses that stand the test of time

  • About
    • Strategy
    • Team
    • Contact Us
  • Company Spotlight
  • News & Insights

NYSE IPO Raises $158M for Cancer Drug Developer BeiGene

Posted in Updates on

On February 2, 2016, BeiGene, which focuses on the discovery and development of innovative cancer drugs, successfully listed on the New York Stock exchange. The listing was the first IPO of the year in the US, raising $158 million. The proceeds will be used to help fund the company’s next stage of clinical trials.

Hillhouse first invested in the company in 2014 in a Series-A investment, believing in the tremendous potential of the company to develop breakthrough cancer treatments.

The listing marked a major step in the development of BeiGene, which was co-founded by John Oyler and Dr. Xiaodong Wang. The success of the IPO in the midst of a difficult environment for global markets was a testament to the strength of the company’s management team and long-term strength.

Filed Under: Updates Tagged With: IPO, Medical

Copyright © 2023 Hillhouse • Terms of Use

  • LinkedIn
  • Instagram
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT